{"id":"placebo-for-apixaban","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL231779","moleculeType":"Small molecule","molecularWeight":"459.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug through comparison. In this case, it serves as the control arm in phase 3 trials of apixaban, a Factor Xa inhibitor anticoagulant. Any observed clinical benefit in the placebo group is attributed to natural disease progression, regression to the mean, or the placebo effect.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:56.454Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in apixaban clinical trials (specific indication depends on parent trial)"}]},"trialDetails":[{"nctId":"NCT05757869","phase":"PHASE3","title":"A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-11","conditions":"Atrial Fibrillation","enrollment":20284},{"nctId":"NCT07015905","phase":"PHASE3","title":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-06-25","conditions":"Venous Thromboembolism (VTE)","enrollment":2000},{"nctId":"NCT04168203","phase":"PHASE4","title":"Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism","enrollment":600},{"nctId":"NCT07160686","phase":"PHASE3","title":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of Birmingham","startDate":"2026-03-02","conditions":"Thromboprophylaxis","enrollment":1456},{"nctId":"NCT03288454","phase":"PHASE2","title":"Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT","status":"COMPLETED","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2017-08-30","conditions":"Healthy","enrollment":60},{"nctId":"NCT04007289","phase":"PHASE3","title":"Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-24","conditions":"Intrahepatic Non Cirrhotic Portal Hypertension","enrollment":166},{"nctId":"NCT04593784","phase":"PHASE2","title":"Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults","status":"TERMINATED","sponsor":"AMAG Pharmaceuticals, Inc.","startDate":"2021-10-13","conditions":"Healthy","enrollment":41},{"nctId":"NCT04650087","phase":"PHASE3","title":"COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis","status":"COMPLETED","sponsor":"Thomas L. Ortel","startDate":"2021-02-15","conditions":"Covid19","enrollment":1291},{"nctId":"NCT03692065","phase":"PHASE3","title":"API-CAT STUDY for APIxaban Cancer Associated Thrombosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-10-11","conditions":"Cancer-associated Thrombosis","enrollment":1766},{"nctId":"NCT05643573","phase":"PHASE3","title":"A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke","status":"TERMINATED","sponsor":"Bayer","startDate":"2022-12-05","conditions":"Prevention of Stroke or Systemic Embolism, Atrial Fibrillation","enrollment":14830},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT03935451","phase":"EARLY_PHASE1","title":"Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2021-09-01","conditions":"IBD, Venous Thromboembolism, Crohn Disease","enrollment":60},{"nctId":"NCT03310021","phase":"PHASE2","title":"A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2017-08-28","conditions":"Bleeding","enrollment":108},{"nctId":"NCT05705076","phase":"NA","title":"Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-01-24","conditions":"Anticoagulants; Increased","enrollment":1100},{"nctId":"NCT04218266","phase":"PHASE2","title":"Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-01-30","conditions":"Atrial Fibrillation (AF)","enrollment":755},{"nctId":"NCT04746339","phase":"PHASE4","title":"Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19","status":"TERMINATED","sponsor":"Brazilian Clinical Research Institute","startDate":"2021-03-04","conditions":"Covid19, Thrombosis","enrollment":411},{"nctId":"NCT04498273","phase":"PHASE3","title":"COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80","status":"TERMINATED","sponsor":"Frank C Sciurba","startDate":"2020-09-07","conditions":"COVID-19","enrollment":657},{"nctId":"NCT03988842","phase":"PHASE4","title":"Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism","status":"TERMINATED","sponsor":"Victor Tapson, MD","startDate":"2019-07-25","conditions":"Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction","enrollment":4},{"nctId":"NCT02415400","phase":"PHASE4","title":"A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-06-04","conditions":"Acute Coronary Syndromes","enrollment":4614},{"nctId":"NCT03590743","phase":"PHASE4","title":"Calf Deep Vein Thrombosis Treatment Trial","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2019-02-19","conditions":"Deep Vein Thrombosis","enrollment":5},{"nctId":"NCT02179177","phase":"PHASE3","title":"Apixaban in Patients With Sickle Cell Disease","status":"TERMINATED","sponsor":"Nirmish Shah","startDate":"2015-01","conditions":"Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease","enrollment":16},{"nctId":"NCT03251482","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-13","conditions":"VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery","enrollment":308},{"nctId":"NCT02048865","phase":"PHASE2","title":"Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2014-03-24","conditions":"Venous Thromboembolism, Cancer","enrollment":575},{"nctId":"NCT02378623","phase":"PHASE2","title":"Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2015-05","conditions":"Patent Foramen Ovale, Cardiac Implantable Electronic Device","enrollment":""},{"nctId":"NCT00320255","phase":"PHASE2","title":"A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-06","conditions":"Thrombosis, Cancer, Pulmonary Embolism","enrollment":130},{"nctId":"NCT00831441","phase":"PHASE3","title":"Phase III Acute Coronary Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03","conditions":"Acute Coronary Syndrome","enrollment":7484},{"nctId":"NCT00371683","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-11","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":3608},{"nctId":"NCT00457002","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":6758},{"nctId":"NCT02074358","phase":"PHASE1","title":"A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Anticoagulation","enrollment":43},{"nctId":"NCT00452530","phase":"PHASE3","title":"Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-06","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":3221},{"nctId":"NCT00423319","phase":"PHASE3","title":"Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-03","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5407},{"nctId":"NCT00643201","phase":"PHASE3","title":"Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Venous Thrombosis","enrollment":5614},{"nctId":"NCT00633893","phase":"PHASE3","title":"Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-05","conditions":"Venous Thrombosis","enrollment":2711},{"nctId":"NCT00852397","phase":"PHASE2","title":"A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-04","conditions":"Acute Coronary Syndrome","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for apixaban","genericName":"Placebo for apixaban","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in apixaban clinical trials (specific indication depends on parent trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}